Skip to main content

Table 1 Multivariate analysis of the enrichment scores of the 3 ir-lncRNAs in cancer

From: Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting

Cancer

Gene name

HR

Cox p value, multivariate

CI lower

CI upper

log rank p, multivariate

Cox p value 3, lncRNAs signature

BRCA

AC092580.4

0.59

0.03

0.37

0.94

0.02

0.03

PCED1B-AS1

1.01

0.90

0.85

1.20

  

RP11-291B21.2

0.98

0.90

0.65

1.46

  

HNSC

AC092580.4

0.98

0.78

0.88

1.10

0.02

2.38E-03

PCED1B-AS1

0.86

0.23

0.68

1.10

  

RP11-291B21.2

0.88

0.18

0.72

1.06

  

RAQA

AC092580.4

3.66E-06

1.00

0.00

Inf

0.50

0.14

PCED1B-AS1

1.00

0.97

0.79

1.28

  

RP11-291B21.2

1.28E-03

1.00

0.00

Inf

  

SKCM

AC092580.4

0.87

0.19

0.70

1.07

0.04

2.38E-03

PCED1B-AS1

0.98

0.71

0.86

1.11

  

RP11-291B21.2

0.97

0.81

0.70

1.27

  

UCEC

AC092580.4

–

–

–

–

0.39

0.01

PCED1B-AS1

0.88

0.39

0.66

1.18

  

RP11-291B21.2

–

–

–

–

  

LIHC

AC092580.4

0.92

0.55

0.70

1.20

0.61

0.06

PCED1B-AS1

1.14

0.46

0.80

1.63

  

RP11-291B21.2

0.57

0.33

0.18

1.76

  

STAD

AC092580.4

0.73

0.01

0.57

0.93

0.09

0.75

PCED1B-AS1

1.02

0.84

0.80

1.30

  

RP11-291B21.2

1.36

0.05

1.00

1.85

  

BLCA

AC092580.4

1.05

0.40

0.93

1.19

0.43

0.07

PCED1B-AS1

0.98

0.70

0.89

1.09

  

RP11-291B21.2

0.87

0.10

0.70

1.05

  

CESC

AC092580.4

0.95

0.60

0.79

1.15

0.06

0.05

PCED1B-AS1

0.66

0.20

0.35

1.25

  

RP11-291B21.2

1.02

0.80

0.83

1.27

  

KICH

AC092580.4

0.01

0.12

1.18E-05

3.91

2.81E-07

0.95

PCED1B-AS1

3.50

0.16

0.62

20.12

  

RP11-291B21.2

877.00

0.51

1.49E-06

5.17E + 11

  

OV

AC092580.4

1.07

0.74

0.70

1.62

0.90

0.62

PCED1B-AS1

0.82

0.44

0.49

1.37

  

RP11-291B21.2

1.03

0.97

0.30

3.50

  

LUSC

AC092580.4

0.96

0.71

0.77

1.20

0.50

0.70

PCED1B-AS1

1.08

0.46

0.88

1.33

  

RP11-291B21.2

0.89

0.41

0.66

1.19

  

READ

AC092580.4

–

–

–

–

0.19

0.27

PCED1B-AS1

0.01

0.24

8.05E-07

35.58

  

RP11-291B21.2

–

–

–

–

  

COAD

AC092580.4

–

–

–

–

0.96

1.00

PCED1B-AS1

0.98

0.96

0.35

2.69

  

RP11-291B21.2

–

–

–

–

  

LUAD

AC092580.4

1.00

0.98

0.90

1.12

0.20

0.42

PCED1B-AS1

0.88

0.05

0.77

1.00

  

RP11-291B21.2

1.04

0.46

0.93

1.17

  

GBM

AC092580.4

0.97

0.86

0.72

1.32

0.10

0.54

PCED1B-AS1

1.00

0.93

0.92

1.08

  

RP11-291B21.2

32.10

0.01

2.03

507.13

  

KIRP

AC092580.4

1.37

0.18

0.86

2.20

1.30E-06

3.33E-03

PCED1B-AS1

0.77

0.05

0.60

1.00

  

RP11-291B21.2

15.50

9.87E-05

3.90

61.58

  

KIRC

AC092580.4

1.03

0.78

0.85

1.24

5.17E-10

0.30

PCED1B-AS1

1.08

0.34

0.92

1.27

  

RP11-291B21.2

1.19

3.00E-03

1.06

1.33

  

LGG

AC092580.4

6.90

1.64E-05

2.87

16.70

3.71E-08

5.82E-07

PCED1B-AS1

0.99

0.84

0.86

1.13

  

RP11-291B21.2

1.28

0.62

0.48

3.40

  
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us